Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.

× No keyword cloud information.

5 in total

1. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.

Authors: Janet A Fairley; Chang Ling Fu; George J Giudice
Journal: J Invest Dermatol Date: 2005-09 Impact factor: 8.551

Review 2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.

Authors: S T Holgate; R Djukanović; T Casale; J Bousquet
Journal: Clin Exp Allergy Date: 2005-04 Impact factor: 5.018

3. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.

Authors: Otobia G Dimson; George J Giudice; Chang Ling Fu; Francoise Van den Bergh; Simon J Warren; Marleen M Janson; Janet A Fairley
Journal: J Invest Dermatol Date: 2003-05 Impact factor: 8.551

4. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice.

Authors: John J Zone; Ted Taylor; Christopher Hull; Linda Schmidt; Laurence Meyer
Journal: J Invest Dermatol Date: 2007-01-18 Impact factor: 8.551

5. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.

Authors: Janet A Fairley; Christopher T Burnett; Chang-Ling Fu; David L Larson; Matthew G Fleming; George J Giudice
Journal: J Invest Dermatol Date: 2007-07-05 Impact factor: 8.551

5 in total

31 in total

Review 1. Off-Label Uses of Omalizumab.

Authors: David El-Qutob
Journal: Clin Rev Allergy Immunol Date: 2016-02 Impact factor: 8.667

Review 2. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors: Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal: Drugs Date: 2018-10 Impact factor: 9.546

Review 3. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors: K A N Messingham; H M Holahan; J A Fairley
Journal: Immunol Res Date: 2014-08 Impact factor: 2.829

4. Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180.

Authors: Kelly A N Messingham; Amber Onoh; Elizabeth M Vanderah; George J Giudice; Janet A Fairley
Journal: Hybridoma (Larchmt) Date: 2012-04

Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.

1. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.

Review 2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.

3. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.

4. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice.

5. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.

Review 1. Off-Label Uses of Omalizumab.

Review 2. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Review 3. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

4. Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180.

5. [Bullous pemphigoid: a new look at a well-known disease].

6. Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

7. T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

8. Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease.

9. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

10. Omalizumab therapy for bullous pemphigoid.